The viral clearance market was valued at USD 530.34 million in 2023 and is projected to reach USD 592.65 million in 2024 and USD 1,464.76 million by 2032, expanding at a CAGR of 12.0% during the forecast period 2024–2032. Growth is anchored in biologics manufacturing, where viral clearance testing underpins the safety of stem cell products, biosimilars, and biopharmaceuticals. The report segments the market by method, application, end user, and region, with North America the largest regional market in 2023. Key players include Charles River Laboratories, Merck KGaA, Sartorius AG, Eurofins Scientific SE, WuXi Biologics, Syngene International Limited, ViruSure GmbH, and Texcell.
Demand Drivers in the Viral Clearance Market
Rapid growth in demand for vaccines and biologics worldwide, linked to rising viral infections and infectious diseases, is a leading driver. According to the World Health Organization, there are over a billion cases of seasonal influenza each year, including around 3–5 million cases of severe illness. Rising R&D investment by pharmaceutical and biotechnology companies in viral clearance processes and techniques is creating new opportunities, alongside a rising number of new drug releases and demand for biopharmaceuticals that treat chronic conditions.
Outsourcing Momentum Among Specialist Providers
The CRO end-user segment is expected to grow at the highest pace. Pharmaceutical and biotechnology companies increasingly outsource early-phase development and laboratory testing, and contract research organizations maintain specialized equipment, facilities, and skilled personnel dedicated to viral clearance. Advances in technology and analytical techniques have further improved the capability of contract research organizations to conduct viral clearance studies. Even so, the pharmaceutical and biotech industry segment led the market overall, as companies focus on new innovations and regulators promote products with reduced viral contamination risks.
Browse Insights;
https://www.polarismarketresearch.com/industry-analysis/viral-clearance-market
Application Segments: Proteins, Blood Products, and Vaccines
Applications include blood and blood products, recombinant proteins, cellular and gene therapy products, vaccines, and others. By method, viral removal accounted for the largest share in 2023, while the viral inactivation segment is projected to grow at the highest rate on rising demand for plasma proteins and gene therapy products. Vaccines held the majority application share in 2023. Blood and blood products are projected to register the highest growth, supported by surging demand in medical treatments, surgeries, and therapeutic interventions, along with rising awareness among health professionals of their benefits. Growing production of recombinant proteins and vaccines is also escalating market growth in North America, reinforcing demand for viral clearance testing services.
Investment in Testing Infrastructure
Recent investments highlight the commercial priority of biosafety testing. In December 2022, WuXi Biologics launched an 8,000-square-meter Biosafety Testing Center to expand capacity for cell bank characterization, virus harvest, unprocessed bulk harvest, and release testing of raw materials of animal origin. In September 2022, MilliporeSigma opened a new viral clearance lab in China within a EUR 29 million biologics testing center, allowing customers to conduct studies locally. In July 2023, Merck announced a USD 70 million investment to expand reagent production in China for quality control and testing. In November 2022, Cygnus Technologies introduced its MockV RVLP Kit to quantify removal of retrovirus-like particles.
Regional Outlook and Market Constraints
North America dominated the viral clearance market in 2023, supported by leading biotechnology and medical institutes and a surge in new drug approvals. Asia Pacific is anticipated to be the fastest-growing region, driven by rising chronic disease and novel infection incidence, growing medical research funding, and a rising number of research organizations in emerging economies. Constraints include the high cost of novel viral clearance technologies and a scarcity of qualified specialists. The market is moderately competitive, with companies competing on efficacy, safety, regulatory compliance, and innovative technologies. The report's Porter's Five Forces analysis rates rivalry among existing firms as high and the threat of new entrants as low. For B2B buyers, partnering with providers that combine viral clearance testing, biosafety testing, and established contract research organizations capabilities offers a practical route to navigating this competitive landscape.
More Trending Latest Reports By Polaris Market Research:
pool-cleaning-and-maintenance-services-market
aluminium-bags-and-pouches-market